BioPharma Services
John Oldenhof has a diverse work experience in the pharmaceutical industry. John is currently serving as the Executive Vice President, Scientific Affairs at BioPharma Services Inc. John'sprevious positions include Vice President Clinical Pharmacology at BioPharma Services Inc., Adjunct Lecturer at the University of Toronto, and Executive Director, Clinical Pharmacology at Syneos Health. John has also held roles at INC Research, Kendle International Inc, Decisionline Clinical Research, Decisionline CRC, Ventana Clinical Research Corporation, and Hemosol. Throughout their career, they have gained expertise in scientific affairs, clinical pharmacology, research consulting, and medical science.
John Oldenhof completed their Bachelor of Science degree in Pharmacology at the University of Toronto - University College from 1987 to 1991. John then pursued their Master's degree in Pharmacology and Toxicology at the University of Toronto from 1991 to 1994. Finally, they obtained their PhD in Pharmacology and Toxicology from the University of Toronto from 1994 to 1999.
BioPharma Services
BioPharma Services Inc. is a full-service Contract Research Organization (CRO) specializing in Phase I/IIa, Bioequivalence, Human Abuse Liability, PET Imaging and Psychedelic Studies. With over 17 years of industry experience, and a primary research facility in Toronto, Canada, our team of experts are dedicated to delivering superior quality service and reliable research results. BioPharma Services offers in-house, GLP/GCP preclinical and clinical bioanalytical services, featuring LC-MS/MS technology at our Toronto facility. We prioritize ethical subject recruitment and comply with all major international regulatory bodies, including the FDA, Health Canada, and ANVISA. We have been successfully inspected by all major regulatory bodies, and are dedicated to building and maintaining long-lasting relationships with our Global clients through superior quality service, timely and reliable research results. Highlights of our experience: → State-of-the-art Clinical facility in Canada with over 150 bed capacity → 99% enrolment for all Phase I studies with a 95% completion rate → Timely study start up: 30 Day CTA, Weekly IRB/Ethics review → 20,000+ active subject database of patients, special populations & healthy volunteers → Full service capabilities: Regulatory, Scientific and Medical Affairs, Comprehensive Project Management, Data Management, Biostatistical Analysis with CDISC data standards (SDTM and ADaM datasets), Medical Writing and more.